|
Variable
|
Group
|
Baseline
|
Week 3
|
Week 6
|
Week 9
|
Week 12
|
P-value*
|
OR (95% CI)
|
|---|
|
MPUT
|
Matrix (n = 20)
|
20 (100)
|
19 (95)
|
18 (90)
|
16 (80)
|
16 (80)a
|
< 0.001
|
2.59 (0.87–7.75)
|
|
Methylphenidate (n = 22)
|
22 (100)
|
20 (90.9)
|
18 (81.8)
|
16 (72.7)
|
13 (59.1)
|
4.95 (1.79–13.68)
|
|
Matrix combination with methylphenidate (n = 21)
|
21 (100)
|
19 (90.5)
|
17 (81)
|
12 (57.1)
|
8 (38.1)
|
7.63 (2.82–20.67)
|
|
Control (n = 22)
|
22 (100)
|
21 (95.5)
|
21 (95.5)
|
20 (90.9)
|
21 (95.5)b
|
Reference
|
- 1 All variables are presented as number (%)
- * GEE analysis (generalized estimating equations)
- a: Significant difference between Matrix and Matrix combination with methylphenidate groups
- b: Significant difference between Control with Methylphenidate and Matrix combination with methylphenidate groups
